• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » New legislation would extend R&D tax credit to CROs

New legislation would extend R&D tax credit to CROs

June 1, 2015
CenterWatch Staff

Two pieces of federal legislation that could extend tax credits to research-centric businesses, including CROs and other companies that conduct clinical research, have been introduced—one in the Senate and one in the House.

The Domestic Research Enhancement Act of 2015 (H.R. 2481), introduced in the House in May, would modernize the R&D tax credit to recognize the role CROs now play in the development of new pharmaceuticals, biologics and medical devices. It also would extend to other industry organizations incurring contracted research expenses.

Currently, only pharmaceutical, biologics and medical device companies receive most of these tax breaks. With the dramatic shift to outsourcing, the federal legislation would include CROs. Two states, Pennsylvania and North Carolina, have more than 13,000 CRO employees combined.

The second legislation, known as COMPETE, would incentivize investment in emerging, research-centric businesses and support cutting-edge technology, including clinical research, with a similar tax credit. It also proposes to reform the rules for how investors can enter into partnerships with small, early-stage R&D companies. It has been introduced in the Senate.

“Research in the life sciences enables us to treat and cure countless life-threatening conditions to improve the quality of life for millions of Americans,” said U.S. Rep. Patrick Meehan (R-Pa.), one of the legislation’s three sponsors, along with Rep. George Holding (R-N.C.) and Rep. G.K. Butterfield (D-N.C.). Meehan said 79,000 jobs in Pennsylvania are dependent on the life sciences.

The proposal would make CROs eligible for a credit of up to 35% of qualifying re­search investments.

“This bipartisan legislation will expand investment in biomedical research, incentiv­ize job creation here at home and strength­en the life sciences workforce so essential to our future and well being,” said Meehan.

Current law, established in 1981, allows sponsors that outsource their research to CROs to claim only 65% of expenses. The majority of those costs are wages under the credit. However, the remaining 35% of ex­penses disappear. Even when CROs acquire research facilities from pharma companies they are not eligible to receive the tax credit.

By contrast, Canada provides a 15% non-refundable federal tax credit on eligible expenditures. This is an incentive for which Canadian CROs generally are eligible, if the R&D funding is received from a foreign client or they encounter cost overruns when work­ing with a Canadian client. France and the U.K. also offer CROs a share of the tax credit.

“This important piece of bipartisan legislation will ensure that the United States remains a leader in medical innovation and encourages employment in the high-wage research sector,” Jamie Macdonald, chair­man of the Association of Clinical Research Organizations (ACRO), said in a statement. “Similar provisions are included in the biparti­san COMPETE Act introduced earlier this year.”

COMPETE, formally known as the Com­petitiveness and Opportunity by Modern­izing and Permanently Extending the Tax Credit for Experimentation Act of 2014 (S.537), was reintroduced in February and would expand and enhance the R&D tax credit for qualifying research investments. It would allow firms undertaking contract-funded research projects to claim a portion of the credit. Under COMPETE, small busi­nesses would be able to enter into a joint venture with an R&D project’s investors, in which the losses and credits generated by the research would then flow through to the company and investors.

“Although the Senate bill is more com­prehensive, the results for CROs would be the same as the Domestic Research En­hancement Act, just with different language, as it is more of a single issue legislation,” said John Lewis, ACRO’s senior vice president of policy and public affairs. “This also is the first time two tax bills have been introduced in Congress that benefit contract research.”

 

Email comments to Ronald at ronald.rosenberg@centerwatch.com. Follow @RonRCW

This article was reprinted from Volume 19, Issue 21, of CWWeekly, a leading clinical research industry newsletter providing expanded analysis on breaking news, study leads, trial results and more. Subscribe »

 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing